A living systematic review and network meta-analysis compared the efficacy and safety of lebrikizumab with other systemic treatments for atopic dermatitis. The study included 98 trials with 24,707 participants. Lebrikizumab showed no significant difference in efficacy outcomes such as Eczema Area and Severity Index (EASI), Patient Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), and Peak Pruritus Numeric Rating Scales (PP-NRS) compared to dupilumab in adults with atopic dermatitis treated for up to 16 weeks. Dupilumab had higher odds of achieving EASI-50, -75, -90, and Investigator Global Assessment success. Other approved systemic medications, including high-dose upadacitinib and abrocitinib, showed numerically higher relative efficacy. Safety outcomes showed low event rates, limiting useful comparisons. The study concluded that lebrikizumab is similarly effective to dupilumab for short-term treatment of atopic dermatitis in adults. Clinicians and patients can use these comparative data to inform treatment decisions. The findings are consistent with other recent systematic reviews, highlighting the comparable efficacy of lebrikizumab to dupilumab. The study also noted that while binary efficacy outcomes favored dupilumab, the differences in efficacy between dupilumab and lebrikizumab on continuous scales were small. The study had limitations, including sparse data on children and limited long-term extension data. The results suggest that lebrikizumab is another effective biologic medication for treating atopic dermatitis.A living systematic review and network meta-analysis compared the efficacy and safety of lebrikizumab with other systemic treatments for atopic dermatitis. The study included 98 trials with 24,707 participants. Lebrikizumab showed no significant difference in efficacy outcomes such as Eczema Area and Severity Index (EASI), Patient Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), and Peak Pruritus Numeric Rating Scales (PP-NRS) compared to dupilumab in adults with atopic dermatitis treated for up to 16 weeks. Dupilumab had higher odds of achieving EASI-50, -75, -90, and Investigator Global Assessment success. Other approved systemic medications, including high-dose upadacitinib and abrocitinib, showed numerically higher relative efficacy. Safety outcomes showed low event rates, limiting useful comparisons. The study concluded that lebrikizumab is similarly effective to dupilumab for short-term treatment of atopic dermatitis in adults. Clinicians and patients can use these comparative data to inform treatment decisions. The findings are consistent with other recent systematic reviews, highlighting the comparable efficacy of lebrikizumab to dupilumab. The study also noted that while binary efficacy outcomes favored dupilumab, the differences in efficacy between dupilumab and lebrikizumab on continuous scales were small. The study had limitations, including sparse data on children and limited long-term extension data. The results suggest that lebrikizumab is another effective biologic medication for treating atopic dermatitis.